EUVIMEDEUVIMED entdecken
Open Access

Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction

Hannah Colldén, Christina E Lundberg, Lena Björck, Björn Redfors, Annika Rosengren, Åsa Tivesten

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.30774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Hannah Colldén und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Ac…. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, 5-alpha Reductase Inhibitors, Androgen Antagonists. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Male sex and endogenous testosterone have been shown to exacerbate neutrophilia and cardiac injury in myocardial infarction (MI), raising questions about protective actions of androgen-modulating drugs in acute ST-elevation MI (STEMI).

Objective

To determine whether the use of 5-alpha reductase inhibitors (5αRIs) or androgen deprivation therapy (ADT), drugs that lower androgen actions, is associated with a reduced frequency of severe complications after percutaneous coronary intervention (PCI)–treated STEMI in men. Design, Setting, and Participants Nationwide, registry-based cohort study of men aged 35 to 84 years with first-time STEMI treated with PCI from January 2006 to December 2022 in Sweden. Propensity score matching was used to match men treated with 5αRIs or ADT with untreated control patients. The primary outcome was a composite of mortality within 30 days and severe in-hospital complications. Data were analyzed in June 2026. Main Outcomes and Measures The primary outcome was a composite of mortality within 30 days and severe in-hospital complications (any of: cardiac arrest and resucitatation, atrioventricular block stage II or III, cardiogenic schock, new-onset atrial fibrillation or flutter, severely depressed left ventricular function, or mechanical complication). Odds ratios were calculated using conditional logistic regression.

Results

In this study of men with PCI-treated STEMI, 1305 men treated with 5αRI (mean [SD] age, 74.2 [6.7] years) were matched to 6463 control patients, and 358 men treated with ADT (mean [SD] age, 76.2 [6.2] years) were matched to 1774 control patients. The odds of experiencing a severe complication were lower in men treated with 5αRIs (odds ratio [OR], 0.80; 95% CI, 0.69-0.93). No significant association was observed for men treated with ADT compared with their matched control patients (OR, 1.10; 95% CI, 0.83-1.45). Conclusions and Relevance In this cohort study of men with PCI-treated STEMI, use of 5αRI but not ADT was associated with a lower risk of severe complications. These results warrant further research into the role of androgens and drugs that affect androgen levels in the acute phase of STEMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ST Elevation Myocardial InfarctionPercutaneous Coronary Intervention5-alpha Reductase InhibitorsAndrogen AntagonistsHumansMaleAgedMiddle AgedSwedenAged, 80 and overAdultRegistriesCohort StudiesPropensity Score

Substanzen

5-alpha Reductase InhibitorsAndrogen Antagonists

Autor:innen und Institutionen

  • Wallenberg Laboratory for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Department of Pharmaceuticals, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • Department of Food and Nutrition and Sport Science, Faculty of Education, University of Gothenburg, Gothenburg, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Cardiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
  • Department of Medicine Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Östra Hospital, Region Västra Götaland, Gothenburg, Sweden.

Zitieren

APA

Colldén, H., Lundberg, C. E., Björck, L., Redfors, B., Rosengren, A., & Tivesten, Å. (2026). Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.30774

Vancouver

Colldén H, Lundberg CE, Björck L, Redfors B, Rosengren A, Tivesten Å. Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.30774

BibTeX
@article{Colldn2026,
  author = {Colldén, Hannah and Lundberg, Christina E and Björck, Lena and Redfors, Björn and Rosengren, Annika and Tivesten, Åsa},
  title = {Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.30774}
}
Kostenlos starten →